格隆汇3月4日｜有投资者在互动平台向诺诚健华提问：公司BD给Zeans公司的奥布，Zeans是否已经开始进行临床试验？目前项目进展怎样？是否会对里程碑付款产生影响？ 诺诚健华回复称，公司已就奥布替尼(orelabrutinib)与Zeans达成对外授权合作。根据协议约定，合作方将负责相关区域内的临床开发及后续商业化推进。公司持续与合作方保持密切沟通，项目正按既定开发计划稳步推进。
Source Link格隆汇3月4日｜有投资者在互动平台向诺诚健华提问：公司BD给Zeans公司的奥布，Zeans是否已经开始进行临床试验？目前项目进展怎样？是否会对里程碑付款产生影响？ 诺诚健华回复称，公司已就奥布替尼(orelabrutinib)与Zeans达成对外授权合作。根据协议约定，合作方将负责相关区域内的临床开发及后续商业化推进。公司持续与合作方保持密切沟通，项目正按既定开发计划稳步推进。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.